|By PR Newswire||
|August 27, 2014 04:17 PM EDT||
BOSTON, Aug. 27, 2014 /PRNewswire/ -- Rhythm, a biopharmaceutical company developing peptide therapeutics that address gastrointestinal diseases and genetic deficiencies that result in metabolic disorders, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
Citigroup and Cowen and Company will act as joint book-running managers for the offering. Canaccord Genuity Inc., Oppenheimer & Co., and Cantor Fitzgerald & Co. will act as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at [email protected], or by calling (800) 831-9146, and from Cowen and Company, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling (631) 274-2806, or by fax at (631) 254-7140.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Rhythm (www.rhythmtx.com)
Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in gastrointestinal diseases and genetic deficiencies that result in metabolic disorders. Rhythm is developing the ghrelin peptide agonist, relamorelin (RM-131), for the treatment of diabetic gastroparesis and other gastrointestinal functional disorders; and the MC4R peptide agonist, RM-493, for obesity caused by genetic deficiencies in the MC4 pathway. The company is based in Boston, Massachusetts.
SOURCE M2 Friend Communications
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Aug. 26, 2016 01:30 AM EDT Reads: 1,654
Aug. 26, 2016 01:15 AM EDT Reads: 2,000
Aug. 26, 2016 01:00 AM EDT Reads: 1,930
Aug. 26, 2016 12:45 AM EDT Reads: 2,227
Aug. 26, 2016 12:30 AM EDT Reads: 2,886
Aug. 25, 2016 11:45 PM EDT Reads: 2,263
Aug. 25, 2016 10:45 PM EDT Reads: 1,861
Aug. 25, 2016 10:15 PM EDT Reads: 1,707
Aug. 25, 2016 09:15 PM EDT Reads: 2,191
Aug. 25, 2016 09:00 PM EDT Reads: 1,693
Aug. 25, 2016 08:45 PM EDT Reads: 1,373
Aug. 25, 2016 06:30 PM EDT Reads: 1,924
Aug. 25, 2016 05:15 PM EDT Reads: 669
Aug. 25, 2016 04:15 PM EDT Reads: 457
Aug. 25, 2016 03:30 PM EDT Reads: 1,492